

iiCONinfection innovation
consortiumINFEX
THERAPEUTICS

Working together to Combat AMR





Critical support for AMR SMEs



World AMR Awareness Week

"Act Now: Protect Our Present, Secure Our Future"





iiCON

infection innovation
consortium



2/5

Moving promising treatments forward

Despite the Anti-Microbial Resistance (AMR) crisis, the funding landscape for SMEs focused on AMR and infectious diseases is particularly challenging, with global investments in antibiotic research continuing to decline.

The Infex and iiCON collaboration has played a pivotal role in supporting Infex to develop this critical pipeline of new drugs, not only through iiCON providing high-impact support to Infex, but also by offering invaluable access to clinical trial expertise, infrastructure, and strategic partnerships.

By bridging the skills and funding gap, iiCON has supported Infex's ongoing work, enabling Infex to continue developing treatments for resistant infections often overlooked by larger pharmaceutical companies.



World AMR Awareness Week

"Act Now: Protect Our Present, Secure Our Future"



iiCONinfection innovation
consortium

3/5

Resp-X: Clinical Readiness and Phase 1 Trials

One of Infex's major programmes, RESP-X, focused on developing treatments for respiratory infections, was supported by iiCON in reaching a significant clinical milestone.

This included access to key resources through iiCON partners such as the University of Liverpool and Liverpool Royal Hospital Clinical Research Facility, expert clinical trial design guidance, and essential operational support.


With iiCON backing, RESP-X reached a major milestone, entering Phase 1 clinical trials in healthy volunteers in Liverpool. The programme is now completing Phase 2a trials with non-cystic fibrosis bronchiectasis (NCFB) patients, marking a critical step toward addressing the urgent need for new therapies in AMR and respiratory infections.



World AMR Awareness Week

"Act Now: Protect Our Present, Secure Our Future"





iiCON

infection innovation
consortium



4/5

Met-X: Pre-Clinical development

Another of Infex's promising programmes, MET-X, which focuses on treating multidrug-resistant bacterial infections, also benefited from iiCON's non-dilutive funding and its network of partners.

iiCON's support helped Infex reach a crucial stage in the MET-X programme – Phase 1 clinical trial readiness. Infex has signed a MOU with ADVANCE-ID, a clinical trials network in Asia to conduct clinical trials to explore the use of MET-X alongside existing licensed therapies.

Infex has also signed an exclusive license agreement for MET-X within the Indian market with Venus Remedies Ltd, which will conduct a Phase I trial for MET-X in combination with meropenem. MET-X is a vital tool to combat broad-spectrum drug-resistant Metallo-beta-lactamase infections, which can cause serious or life-threatening illnesses in patients.



World AMR Awareness Week

"Act Now: Protect Our Present, Secure Our Future"



Cov-X: Hits to Leads to Pre-Clinical Development

The COV-X programme, focused on tackling COVID-19 and broad spectrum coronavirus infections, also received critical backing from iiCON.

The programme progressed from hits-to-leads (the identification of potential drug candidates) with the aid of iiCON's expertise, before receiving further funding from Innovate UK, part of UK Research and Innovation, for candidate nomination.

The programme also received grant funding from US Federal Government Agency, the National Institute of Allergy and Infectious Diseases (NIAID), for pre-clinical development, ensuring continued progress of the asset to tackle pandemic infections.



World AMR Awareness Week

"Act Now: Protect Our Present, Secure Our Future"





infection innovation
consortium



5/5

Working together to accelerate AMR Innovation

iiCON has a network of c1,000 companies and organisations world-wide, we are working with our partners to advance innovative solutions for some of the world's most challenging infectious diseases.

To find out more about our work to support leading-edge innovation or get in touch with the team at iiCON, visit:



www.infectioninnovation.com



World AMR Awareness Week

"Act Now: Protect Our Present, Secure Our Future"

